Share Price and Basic Stock Data
Last Updated: January 21, 2026, 9:50 pm
| PEG Ratio | 4.99 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajanta Pharma Ltd operates within the pharmaceuticals sector, focusing on the development and manufacturing of generic and specialty drugs. The company’s stock price stood at ₹2,705, with a market capitalization of ₹33,801 Cr. Over recent years, Ajanta Pharma has demonstrated a robust upward trajectory in sales, recording ₹3,743 Cr in revenue for the fiscal year ending March 2023, an increase from ₹3,341 Cr in the previous year. In Q2 FY2025, the company reported sales of ₹1,028 Cr, reflecting a consistent growth pattern with a quarter-on-quarter increase. The company’s revenue from operations is projected to reach ₹4,973 Cr for the trailing twelve months (TTM), showcasing its strong position in the market. The operating profit margin (OPM) recorded at 24% indicates efficient cost management, reinforcing the company’s capability to convert sales into profits effectively. The pharmaceutical industry in India has been growing at a compounded annual growth rate (CAGR) of around 12% over the past few years, positioning Ajanta Pharma favorably against its peers.
Profitability and Efficiency Metrics
Ajanta Pharma has demonstrated impressive profitability metrics, with a reported net profit of ₹974 Cr for the TTM period. The company’s return on equity (ROE) stood at 24.9%, significantly higher than the industry average of around 15%, indicating effective utilization of shareholder funds. The return on capital employed (ROCE) was reported at 32.4%, showcasing the company’s capability to generate returns from its capital investments. The operating profit for the fiscal year ending March 2024 is anticipated to be ₹1,172 Cr, with an OPM of 28%, reflecting improved operational efficiency. Furthermore, the interest coverage ratio (ICR) of 65.32x highlights the company’s strong ability to meet interest obligations, providing a buffer against financial distress. However, the cash conversion cycle (CCC) of 246 days could be a concern, as it indicates a longer period for converting investments in inventory and receivables back into cash.
Balance Sheet Strength and Financial Ratios
Ajanta Pharma’s balance sheet reflects a solid financial position, with total assets amounting to ₹5,672 Cr as of September 2025. The company reported reserves of ₹4,290 Cr, underscoring its capacity to fund future growth initiatives. The borrowings stood at ₹246 Cr, which is relatively low compared to the equity base, resulting in a debt-to-equity ratio that remains manageable. The company’s book value per share was ₹302.38, providing a strong cushion for investors. Ajanta Pharma’s current ratio of 2.85 and quick ratio of 1.95 indicate a strong liquidity position, ensuring it can cover short-term liabilities effectively. Additionally, the price-to-book value (P/BV) ratio of 8.66x suggests that the stock is trading at a premium compared to its book value, reflecting investor confidence in its growth prospects. However, the enterprise value (EV) of ₹32,649.25 Cr and the EV/EBITDA ratio of 24.11x may imply a relatively high valuation in the context of earnings.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ajanta Pharma indicates a stable ownership structure, with promoters holding 66.25% of the equity, reinforcing management’s control and commitment to the company. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 8.53% and 17.90%, respectively, reflecting a healthy interest from institutional players. The public shareholding stands at 7.32%, which is modest. Over the past year, the promoter holding has remained relatively stable, varying slightly, which suggests confidence in the company’s strategic direction. The number of shareholders has increased to 67,785, indicating growing retail investor interest. However, the slight decline in FII ownership from 10.07% in December 2022 to 8.53% in September 2025 may raise concerns about international investor sentiment. Overall, the stable promoter holding and growing retail participation highlight investor confidence in Ajanta Pharma’s business model and future growth potential.
Outlook, Risks, and Final Insight
Looking ahead, Ajanta Pharma is well-positioned to capitalize on the growth of the pharmaceutical industry in India, driven by increasing healthcare demands and a focus on generic drugs. Strengths include strong profitability metrics, a solid balance sheet, and a stable shareholding structure that supports long-term strategic decisions. However, risks such as the extended cash conversion cycle may impact liquidity, and fluctuating FII interest could signal changing investor perceptions. Additionally, the high valuation multiples may deter some value-focused investors. The company’s ability to maintain operational efficiency and navigate regulatory challenges will be crucial for sustaining growth. In the event of continued revenue growth and effective cost management, Ajanta Pharma could emerge as a leader in the sector, while any significant disruptions could challenge its operational stability and market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 203/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,425 Cr. | 315 | 479/192 | 70.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 59.6 Cr. | 40.7 | 41.6/17.0 | 142 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,413.05 Cr | 1,082.65 | 47.91 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 938 | 972 | 882 | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 |
| Expenses | 742 | 802 | 732 | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 |
| Operating Profit | 196 | 170 | 149 | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 |
| OPM % | 21% | 17% | 17% | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% |
| Other Income | 40 | 35 | 37 | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 |
| Interest | 1 | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 |
| Depreciation | 33 | 33 | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 |
| Profit before tax | 203 | 168 | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 |
| Tax % | 23% | 20% | 20% | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% |
| Net Profit | 157 | 135 | 122 | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 |
| EPS in Rs | 12.22 | 10.50 | 9.54 | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 |
Last Updated: January 2, 2026, 2:03 pm
Below is a detailed analysis of the quarterly data for Ajanta Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,303.00 Cr. (Jun 2025) to 1,354.00 Cr., marking an increase of 51.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,026.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 951.00 Cr. (Jun 2025) to 1,026.00 Cr., marking an increase of 75.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 328.00 Cr.. The value appears to be declining and may need further review. It has decreased from 351.00 Cr. (Jun 2025) to 328.00 Cr., marking a decrease of 23.00 Cr..
- For OPM %, as of Sep 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Jun 2025) to 24.00%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 59.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Jun 2025) to 59.00 Cr., marking an increase of 33.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 41.00 Cr. (Jun 2025) to 43.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 341.00 Cr.. The value appears strong and on an upward trend. It has increased from 331.00 Cr. (Jun 2025) to 341.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Jun 2025) to 24.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 260.00 Cr.. The value appears strong and on an upward trend. It has increased from 255.00 Cr. (Jun 2025) to 260.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 20.83. The value appears strong and on an upward trend. It has increased from 20.44 (Jun 2025) to 20.83, marking an increase of 0.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 4,973 |
| Expenses | 840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 3,676 |
| Operating Profit | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,297 |
| OPM % | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 26% |
| Other Income | 14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 85 | 134 |
| Interest | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 | 23 |
| Depreciation | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 | 160 |
| Profit before tax | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,249 |
| Tax % | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% | |
| Net Profit | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 974 |
| EPS in Rs | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 77.94 |
| Dividend Payout % | 15% | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.48% | 34.19% | 21.88% | -7.50% | -17.48% | 20.93% | 39.74% | 9.02% | -17.53% | 38.78% | 12.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -12.32% | -29.37% | -9.99% | 38.41% | 18.81% | -30.72% | -26.55% | 56.31% | -26.03% |
Ajanta Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 21% |
| 3 Years: | 25% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 22% |
| 3 Years: | 22% |
| Last Year: | 25% |
Last Updated: September 4, 2025, 10:30 pm
Balance Sheet
Last Updated: December 4, 2025, 12:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 | 25 |
| Reserves | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,765 | 4,290 |
| Borrowings | 130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 47 | 246 |
| Other Liabilities | 226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 1,067 | 1,112 |
| Total Liabilities | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
| Fixed Assets | 279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,762 | 1,873 |
| CWIP | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 | 146 |
| Investments | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 464 | 874 |
| Other Assets | 513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,502 | 2,779 |
| Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
Below is a detailed analysis of the balance sheet data for Ajanta Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,765.00 Cr. (Mar 2025) to 4,290.00 Cr., marking an increase of 525.00 Cr..
- For Borrowings, as of Sep 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2025) to 246.00 Cr., marking an increase of 199.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,067.00 Cr. (Mar 2025) to 1,112.00 Cr., marking an increase of 45.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,672.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,762.00 Cr. (Mar 2025) to 1,873.00 Cr., marking an increase of 111.00 Cr..
- For CWIP, as of Sep 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2025) to 146.00 Cr., marking a decrease of 30.00 Cr..
- For Investments, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 410.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,779.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,502.00 Cr. (Mar 2025) to 2,779.00 Cr., marking an increase of 277.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,672.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
Notably, the Reserves (4,290.00 Cr.) exceed the Borrowings (246.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 433.00 | 513.00 | 690.00 | 656.00 | 531.00 | 608.00 | -30.00 | 908.00 | 772.00 | -34.00 | -46.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 93 |
| Inventory Days | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 308 |
| Days Payable | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 155 |
| Cash Conversion Cycle | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 246 |
| Working Capital Days | 39 | 56 | 78 | 65 | 103 | 113 | 108 | 126 | 140 | 83 | 119 | 97 |
| ROCE % | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 32% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,674,471 | 0.63 | 428.8 | 1,977,744 | 2025-12-08 07:42:13 | -15.33% |
| UTI Flexi Cap Fund | 1,425,000 | 1.43 | 364.91 | 1,415,187 | 2025-12-14 16:27:00 | 0.69% |
| Kotak Small Cap Fund | 1,219,302 | 1.79 | 312.24 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 959,323 | 2.9 | 245.66 | 968,214 | 2025-12-08 04:19:42 | -0.92% |
| Canara Robeco Large and Mid Cap Fund | 928,520 | 0.91 | 237.78 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 897,224 | 0.8 | 229.76 | N/A | N/A | N/A |
| UTI Mid Cap Fund | 840,000 | 1.79 | 215.11 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 807,460 | 0.41 | 206.77 | 628,966 | 2025-12-08 02:19:27 | 28.38% |
| Canara Robeco Small Cap Fund | 579,013 | 1.14 | 148.27 | 546,991 | 2025-12-07 16:44:29 | 5.85% |
| PGIM India Midcap Fund | 454,661 | 1.01 | 116.43 | 424,692 | 2025-12-14 03:33:18 | 7.06% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 73.56 | 64.82 | 45.89 | 82.45 | 75.09 |
| Diluted EPS (Rs.) | 73.53 | 64.77 | 45.89 | 82.45 | 75.09 |
| Cash EPS (Rs.) | 84.92 | 75.31 | 56.89 | 97.61 | 88.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Revenue From Operations / Share (Rs.) | 370.81 | 333.10 | 296.21 | 389.17 | 332.34 |
| PBDIT / Share (Rs.) | 108.02 | 99.45 | 69.80 | 121.72 | 117.83 |
| PBIT / Share (Rs.) | 96.52 | 88.73 | 59.45 | 107.13 | 104.48 |
| PBT / Share (Rs.) | 94.87 | 88.16 | 58.98 | 105.94 | 103.53 |
| Net Profit / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| NP After MI And SOA / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| PBDIT Margin (%) | 29.13 | 29.85 | 23.56 | 31.27 | 35.45 |
| PBIT Margin (%) | 26.02 | 26.63 | 20.06 | 27.52 | 31.43 |
| PBT Margin (%) | 25.58 | 26.46 | 19.91 | 27.22 | 31.15 |
| Net Profit Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| NP After MI And SOA Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| Return on Networth / Equity (%) | 24.28 | 22.87 | 17.35 | 21.83 | 21.82 |
| Return on Capital Employeed (%) | 30.10 | 29.95 | 21.21 | 26.98 | 29.02 |
| Return On Assets (%) | 18.35 | 17.59 | 12.56 | 17.57 | 17.30 |
| Asset Turnover Ratio (%) | 0.96 | 0.90 | 0.81 | 0.83 | 0.79 |
| Current Ratio (X) | 2.85 | 3.05 | 2.49 | 3.50 | 3.13 |
| Quick Ratio (X) | 1.95 | 2.12 | 1.77 | 2.28 | 1.94 |
| Inventory Turnover Ratio (X) | 5.37 | 1.14 | 1.19 | 1.10 | 1.25 |
| Dividend Payout Ratio (NP) (%) | 38.00 | 78.68 | 15.25 | 11.53 | 12.67 |
| Dividend Payout Ratio (CP) (%) | 32.85 | 67.48 | 12.47 | 9.81 | 10.76 |
| Earning Retention Ratio (%) | 62.00 | 21.32 | 84.75 | 88.47 | 87.33 |
| Cash Earning Retention Ratio (%) | 67.15 | 32.52 | 87.53 | 90.19 | 89.24 |
| Interest Coverage Ratio (X) | 65.32 | 174.28 | 151.01 | 102.45 | 123.89 |
| Interest Coverage Ratio (Post Tax) (X) | 45.40 | 114.20 | 101.68 | 70.87 | 80.07 |
| Enterprise Value (Cr.) | 32649.25 | 28149.11 | 14945.61 | 15321.67 | 15384.30 |
| EV / Net Operating Revenue (X) | 7.02 | 6.69 | 3.99 | 4.59 | 5.32 |
| EV / EBITDA (X) | 24.11 | 22.40 | 16.95 | 14.66 | 15.02 |
| MarketCap / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| Retention Ratios (%) | 61.99 | 21.31 | 84.74 | 88.46 | 87.32 |
| Price / BV (X) | 8.66 | 7.93 | 4.51 | 4.76 | 5.21 |
| Price / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| EarningsYield | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 |
After reviewing the key financial ratios for Ajanta Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 73.56. This value is within the healthy range. It has increased from 64.82 (Mar 24) to 73.56, marking an increase of 8.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 73.53. This value is within the healthy range. It has increased from 64.77 (Mar 24) to 73.53, marking an increase of 8.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 84.92. This value is within the healthy range. It has increased from 75.31 (Mar 24) to 84.92, marking an increase of 9.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 370.81. It has increased from 333.10 (Mar 24) to 370.81, marking an increase of 37.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 108.02. This value is within the healthy range. It has increased from 99.45 (Mar 24) to 108.02, marking an increase of 8.57.
- For PBIT / Share (Rs.), as of Mar 25, the value is 96.52. This value is within the healthy range. It has increased from 88.73 (Mar 24) to 96.52, marking an increase of 7.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 94.87. This value is within the healthy range. It has increased from 88.16 (Mar 24) to 94.87, marking an increase of 6.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For PBDIT Margin (%), as of Mar 25, the value is 29.13. This value is within the healthy range. It has decreased from 29.85 (Mar 24) to 29.13, marking a decrease of 0.72.
- For PBIT Margin (%), as of Mar 25, the value is 26.02. This value exceeds the healthy maximum of 20. It has decreased from 26.63 (Mar 24) to 26.02, marking a decrease of 0.61.
- For PBT Margin (%), as of Mar 25, the value is 25.58. This value is within the healthy range. It has decreased from 26.46 (Mar 24) to 25.58, marking a decrease of 0.88.
- For Net Profit Margin (%), as of Mar 25, the value is 19.80. This value exceeds the healthy maximum of 10. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.80. This value is within the healthy range. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 22.87 (Mar 24) to 24.28, marking an increase of 1.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 30.10. This value is within the healthy range. It has increased from 29.95 (Mar 24) to 30.10, marking an increase of 0.15.
- For Return On Assets (%), as of Mar 25, the value is 18.35. This value is within the healthy range. It has increased from 17.59 (Mar 24) to 18.35, marking an increase of 0.76.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has increased from 0.90 (Mar 24) to 0.96, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 2.85, marking a decrease of 0.20.
- For Quick Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.95, marking a decrease of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 5.37, marking an increase of 4.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 38.00. This value is within the healthy range. It has decreased from 78.68 (Mar 24) to 38.00, marking a decrease of 40.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 32.85. This value is within the healthy range. It has decreased from 67.48 (Mar 24) to 32.85, marking a decrease of 34.63.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.00. This value is within the healthy range. It has increased from 21.32 (Mar 24) to 62.00, marking an increase of 40.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 67.15. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 67.15, marking an increase of 34.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.32. This value is within the healthy range. It has decreased from 174.28 (Mar 24) to 65.32, marking a decrease of 108.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.40. This value is within the healthy range. It has decreased from 114.20 (Mar 24) to 45.40, marking a decrease of 68.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 32,649.25. It has increased from 28,149.11 (Mar 24) to 32,649.25, marking an increase of 4,500.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.02. This value exceeds the healthy maximum of 3. It has increased from 6.69 (Mar 24) to 7.02, marking an increase of 0.33.
- For EV / EBITDA (X), as of Mar 25, the value is 24.11. This value exceeds the healthy maximum of 15. It has increased from 22.40 (Mar 24) to 24.11, marking an increase of 1.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For Retention Ratios (%), as of Mar 25, the value is 61.99. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 61.99, marking an increase of 40.68.
- For Price / BV (X), as of Mar 25, the value is 8.66. This value exceeds the healthy maximum of 3. It has increased from 7.93 (Mar 24) to 8.66, marking an increase of 0.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajanta Pharma Ltd:
- Net Profit Margin: 19.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.1% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 24.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 45.4
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.8 (Industry average Stock P/E: 47.91)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ajanta House, Charkop, Kandivli (West), Mumbai Maharashtra 400067 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mannalal B Agrawal | Chairman |
| Mr. Madhusudan B Agrawal | Vice Chairman |
| Mr. Yogesh M Agrawal | Managing Director |
| Mr. Rajesh M Agrawal | Joint Managing Director |
| Mr. David Rasquinha | Independent Director |
| Ms. Medha Joshi | Independent Director |
| Mr. Rajesh Dalal | Independent Director |
| Ms. Simi Thapar | Independent Director |
FAQ
What is the intrinsic value of Ajanta Pharma Ltd?
Ajanta Pharma Ltd's intrinsic value (as of 21 January 2026) is ₹2584.81 which is 4.73% lower the current market price of ₹2,713.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹33,900 Cr. market cap, FY2025-2026 high/low of ₹3,080/2,022, reserves of ₹4,290 Cr, and liabilities of ₹5,672 Cr.
What is the Market Cap of Ajanta Pharma Ltd?
The Market Cap of Ajanta Pharma Ltd is 33,900 Cr..
What is the current Stock Price of Ajanta Pharma Ltd as on 21 January 2026?
The current stock price of Ajanta Pharma Ltd as on 21 January 2026 is ₹2,713.
What is the High / Low of Ajanta Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajanta Pharma Ltd stocks is ₹3,080/2,022.
What is the Stock P/E of Ajanta Pharma Ltd?
The Stock P/E of Ajanta Pharma Ltd is 34.8.
What is the Book Value of Ajanta Pharma Ltd?
The Book Value of Ajanta Pharma Ltd is 345.
What is the Dividend Yield of Ajanta Pharma Ltd?
The Dividend Yield of Ajanta Pharma Ltd is 1.03 %.
What is the ROCE of Ajanta Pharma Ltd?
The ROCE of Ajanta Pharma Ltd is 32.4 %.
What is the ROE of Ajanta Pharma Ltd?
The ROE of Ajanta Pharma Ltd is 24.9 %.
What is the Face Value of Ajanta Pharma Ltd?
The Face Value of Ajanta Pharma Ltd is 2.00.